Pasithea Cash from 2010 to 2024
| KTTA Stock | USD 2.67 0.13 5.12% |
Cash | First Reported 2010-12-31 | Previous Quarter 16.3 M | Current Value 28.2 M | Quarterly Volatility 16.4 M |
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 680.9 K, Interest Expense of 224 or Other Operating Expenses of 9.9 M, as well as many indicators such as Price To Sales Ratio of 36.39, Dividend Yield of 0.0 or PTB Ratio of 0.38. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
Pasithea | Cash |
Latest Pasithea Therapeutics' Cash Growth Pattern
Below is the plot of the Cash of Pasithea Therapeutics Corp over the last few years. Cash refers to the most liquid asset of Pasithea Therapeutics, which is listed under current asset account on Pasithea Therapeutics Corp balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Pasithea Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Pasithea Therapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Pasithea Therapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pasithea Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Pasithea Cash Regression Statistics
| Arithmetic Mean | 8,890,939 | |
| Geometric Mean | 879,393 | |
| Coefficient Of Variation | 184.89 | |
| Mean Deviation | 12,682,691 | |
| Median | 243,650 | |
| Standard Deviation | 16,438,783 | |
| Sample Variance | 270.2T | |
| Range | 52.7M | |
| R-Value | 0.65 | |
| Mean Square Error | 168.5T | |
| R-Squared | 0.42 | |
| Significance | 0.01 | |
| Slope | 2,385,365 | |
| Total Sum of Squares | 3783.3T |
Pasithea Cash History
Other Fundumenentals of Pasithea Therapeutics
| Cash And Short Term Investments | ||
| Change In Cash | ||
| Free Cash Flow | ||
| Total Cashflows From Investing Activities |
Pasithea Therapeutics Cash component correlations
Click cells to compare fundamentals
About Pasithea Therapeutics Financial Statements
Pasithea Therapeutics stakeholders use historical fundamental indicators, such as Pasithea Therapeutics' Cash, to determine how well the company is positioned to perform in the future. Although Pasithea Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pasithea Therapeutics' assets and liabilities are reflected in the revenues and expenses on Pasithea Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pasithea Therapeutics Corp. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cash | 16.3 M | 28.2 M | |
| Cash And Short Term Investments | 16.3 M | 28.2 M | |
| Change In Cash | -16.8 K | -15.9 K | |
| Free Cash Flow | -13.5 M | -12.8 M | |
| Total Cashflows From Investing Activities | -19.4 K | -20.3 K | |
| Other Cashflows From Financing Activities | 399 K | 379.1 K | |
| Other Non Cash Items | -121.3 K | -127.4 K | |
| Total Cash From Operating Activities | -12.8 M | -12.2 M | |
| Total Cash From Financing Activities | -3.7 M | -3.5 M | |
| End Period Cash Flow | 16.3 M | 28.2 M | |
| Begin Period Cash Flow | 33.1 M | 31.6 M | |
| Other Cashflows From Investing Activities | 433.3 K | 455 K | |
| Free Cash Flow Yield | (1.44) | (1.37) | |
| Operating Cash Flow Per Share | (0.01) | (0.01) | |
| Free Cash Flow Per Share | (10.67) | (11.20) | |
| Cash Per Share | 12.94 | 17.12 | |
| EV To Operating Cash Flow | 514.74 | 540.48 | |
| EV To Free Cash Flow | 0.51 | 0.54 | |
| Price To Operating Cash Flows Ratio | (695.61) | (730.39) | |
| Price To Free Cash Flows Ratio | (0.69) | (0.73) | |
| Cash Ratio | 6.20 | 5.89 | |
| Operating Cash Flow Sales Ratio | (26.94) | (28.28) | |
| Free Cash Flow Operating Cash Flow Ratio | 1 K | 1.1 K | |
| Price Cash Flow Ratio | (695.61) | (730.39) | |
| Cash Conversion Cycle | -4.3 K | -4.5 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:Check out the analysis of Pasithea Therapeutics Correlation against competitors. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.79) | Revenue Per Share 0.37 | Quarterly Revenue Growth 14.981 | Return On Assets (0.38) | Return On Equity (0.63) |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.